Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 319

1.

Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity.

Rosário PW, Borges MA, Purisch S.

J Nucl Med. 2008 Nov;49(11):1776-82. doi: 10.2967/jnumed.108.050591.

2.

Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.

Freudenberg LS, Frömke C, Petrich T, Marlowe RJ, Koska WW, Brandau W, Eising EG, Knust EJ, Bockisch A, Jentzen W.

Exp Clin Endocrinol Diabetes. 2010 Jul;118(7):393-9. doi: 10.1055/s-0029-1225350.

PMID:
19856257
3.

Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.

Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C.

J Nucl Med. 2006 Apr;47(4):648-54.

4.

Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.

Vianello F, Mazzarotto R, Mian C, Lora O, Saladini G, Servodio O, Basso M, Pennelli G, Pelizzo MR, Sotti G.

Clin Oncol (R Coll Radiol). 2012 Apr;24(3):162-8. doi: 10.1016/j.clon.2011.02.011.

PMID:
21411300
5.

Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.

Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, Fleisher M, Robbins RJ.

J Nucl Med. 2008 May;49(5):764-70. doi: 10.2967/jnumed.107.049072.

6.

Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.

Taïeb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara B, De Micco C, Vaillant J, Thomas S, Conte-Devolx B, Loundou A, Auquier P, Henry JF, Mundler O.

Clin Endocrinol (Oxf). 2009 Jul;71(1):115-23. doi: 10.1111/j.1365-2265.2008.03424.x.

PMID:
18803678
7.

rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.

Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F.

Endocr Relat Cancer. 2005 Mar;12(1):49-64. Review.

8.

Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.

Taïeb D, Sebag F, Farman-Ara B, Portal T, Baumstarck-Barrau K, Fortanier C, Bourrelly M, Mancini J, De Micco C, Auquier P, Conte-Devolx B, Henry JF, Mundler O.

J Clin Endocrinol Metab. 2010 Jul;95(7):3283-90. doi: 10.1210/jc.2009-2528.

PMID:
20392868
9.

Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.

Grewal RK, Larson SM, Pentlow CE, Pentlow KS, Gonen M, Qualey R, Natbony L, Tuttle RM.

J Nucl Med. 2009 Oct;50(10):1605-10. doi: 10.2967/jnumed.108.061382.

11.

Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants.

Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Turco A, Mariani G.

Nucl Med Commun. 2006 Aug;27(8):627-32.

PMID:
16829763
12.

Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.

Nieuwlaat WA, Hermus AR, Ross HA, Buijs WC, Edelbroek MA, Bus JW, Corstens FH, Huysmans DA.

J Nucl Med. 2004 Apr;45(4):626-33.

13.

Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.

Giovanella L, Ceriani L, Suriano S, Ghelfo A, Maffioli M.

Clin Endocrinol (Oxf). 2008 Oct;69(4):659-63. doi: 10.1111/j.1365-2265.2008.03244.x.

PMID:
18363882
14.

Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.

Molinaro E, Giani C, Agate L, Biagini A, Pieruzzi L, Bianchi F, Brozzi F, Ceccarelli C, Viola D, Piaggi P, Vitti P, Pacini F, Elisei R.

J Clin Endocrinol Metab. 2013 Jul;98(7):2693-700. doi: 10.1210/jc.2012-4137.

PMID:
23626005
15.

Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?

Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, Zhao S, Tamaki N, Noguchi Y, Noguchi S.

J Nucl Med. 2005 Feb;46(2):261-6.

16.

Recombinant human thyrotropin (rhTSH) in the follow-up and treatment of patients with thyroid cancer.

Bombardieri E, Seregni E, Villano C, Aliberti G, Mattavelli F.

Tumori. 2003 Sep-Oct;89(5):533-6. Review.

PMID:
14870779
17.

Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.

Pötzi C, Moameni A, Karanikas G, Preitfellner J, Becherer A, Pirich C, Dudczak R.

Clin Endocrinol (Oxf). 2006 Oct;65(4):519-23.

PMID:
16984246
18.

Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.

Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C.

J Clin Endocrinol Metab. 2006 Mar;91(3):926-32.

PMID:
16384850
19.

High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.

Romão R, Rubio IG, Tomimori EK, Camargo RY, Knobel M, Medeiros-Neto G.

Thyroid. 2009 Sep;19(9):945-51. doi: 10.1089/thy.2008.0394.

PMID:
19678745
20.

rhTSH-aided low-activity versus high-activity regimens of radioiodine in residual ablation for differentiated thyroid cancer: a meta-analysis.

Ma C, Tang L, Fu H, Li J, Wang H.

Nucl Med Commun. 2013 Dec;34(12):1150-6. doi: 10.1097/MNM.0b013e328365ac05. Review.

Items per page

Supplemental Content

Support Center